Monascuspiloin

Monascuspiloin (Monascinol) exhibits anti-androgenic activity with an IC50 of 7 μM. Monascuspiloin inhibits viability of PC-3 and LNCaP with IC50 of 45 and 47 μM. Monascuspiloin induces apoptosis in LNCaP through inhibition of Akt/mTOR signaling pathway, induces autophagy through activation AMPK signaling pathway and arrest cell cycle at G2/M phase in PC-3. Monascuspiloin exhibits antitumor efficacy in mice[1][2].

Product Specifications

CAS Number

[1011244-19-1]

Product Name Alternative

Monascinol

UNSPSC

12352005

Target

Akt; AMPK; Androgen Receptor; Apoptosis; Autophagy; mTOR

Type

Natural Products

Related Pathways

Apoptosis; Autophagy; Epigenetics; PI3K/Akt/mTOR; Vitamin D Related/Nuclear Receptor

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/monascuspiloin.html

Purity

Smiles

C[C@]12[C@@](CC3=C(COC(/C=C/C)=C3)C2=O)([H])[C@H](C(O1)=O)[C@@H](O)CCCCC

Molecular Formula

C21H28O5

Molecular Weight

360.44

References & Citations

[1]Chen RJ, et al., Monascuspiloin induces apoptosis and autophagic cell death in human prostate cancer cells via the Akt and AMPK signaling pathways. J Agric Food Chem. 2012 Jul 25;60 (29) :7185-93. |[2]Chiu HW, et al., Monascuspiloin enhances the radiation sensitivity of human prostate cancer cells by stimulating endoplasmic reticulum stress and inducing autophagy. PLoS One. 2012;7 (7) :e40462.